It has been reported that diarrhea occurred in 27%–54% of cancer patients treated with CTLA‐4 inhibitors, and colitis in 8%–22%.11 GI adverse events are the most commonly reported irAEs of CTLA‐4 inhibitors, with the earliest onset and very severe symptoms which often leads to treatment discontinuation. Here, CTLA4 is linked to colitis.